Vir Biotechnology
206 hedge funds and large institutions have $887M invested in Vir Biotechnology in 2023 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 69 increasing their positions, 73 reducing their positions, and 33 closing their positions.
59% more call options, than puts
Call options by funds: $3.64M | Put options by funds: $2.3M
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.22% less ownership
Funds ownership: 65.77% → 65.55% (-0.22%)
0% less capital inflows, than outflows
Capital inflows: $80.1M | Capital outflows: $80.4M
5% less repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 73
4% less funds holding
Funds holding: 214 → 206 (-8)
15% less first-time investments, than exits
New positions opened: 28 | Existing positions closed: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$27M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$10M |
| 3 |
BlackRock
New York
|
+$9.69M |
| 4 |
Morgan Stanley
New York
|
+$6.75M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$12.5M |
| 2 |
Norges Bank
Oslo,
Norway
|
-$9.66M |
| 3 |
Jupiter Asset Management
London,
United Kingdom
|
-$6.64M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5.57M |
| 5 |
Algert Global
San Francisco,
California
|
-$3.82M |
VIR Hedge Fund Activity: Q4 2023 in Review
206 of the 6,873 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q4 2023, worth a combined $887M — up 7.2% from $827M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of VIR and 28 opened new positions — a net loss of 5 holders — while 73 trimmed existing stakes and 69 added.
The largest buyer was Citadel Advisors, adding an estimated $27M. The largest seller was American Century Companies, cutting an estimated $12.5M.
- 206 institutional investors held Vir Biotechnology (VIR) as of Q4 2023, down from 214 in Q3 2023.
- Funds reported $887M of Vir Biotechnology stock for Q4 2023, up 7.2% quarter-over-quarter.
- 28 funds opened new Vir Biotechnology positions in Q4 2023 and 33 closed out, a net change of -5 holders.
- The largest Vir Biotechnology buyer in Q4 2023 was Citadel Advisors, an estimated $27M added.
- The largest Vir Biotechnology seller in Q4 2023 was American Century Companies, an estimated $12.5M sold.
Based on aggregated 13F filings for Q4 2023.